Clinical deterioration during neutropenia recovery after G-CSF therapy in patient with COVID-19

Muhanad Taha a,*, Aditi Sharma b, Ayman Soubani c

a Internal Medicine Resident PGY3, Department of Internal Medicine Detroit Medical Centre, Wayne State University, 4201 St Antoine UHC 2E Detroit, MI, 48201, USA
b Internal Medicine Resident PGY 2, Department of Internal Medicine, Detroit Medical Centre, Wayne State University, 4201 St Antoine UHC 2E Detroit, MI, 48201, USA
c Department of Pulmonary Critical Care & Sleep Division, Wayne State University, Harper University Hospital 3990 John R - 3 Hudson Detroit, MI, 48201, USA

A 47-year-old male who received a kidney transplant seven years ago was admitted to the hospital during Covid-19 pandemic because of diarrhea, nausea, vomiting and acute kidney injury. The patient had been in his usual state of health until 2 weeks before admission, when nausea, vomiting and diarrhea developed. He had not been able to drink or eat since his symptoms started. He called his primary care physician, who suggested that he present to the emergency department for further evaluation.

In the emergency department, the patient reported ongoing nausea and abdominal discomfort. He vomited once in emergency department. He had no shortness of breath, cough, fever, or chills. He had not traveled recently and had no known contact with sick person.

Other medical history was notable for type two diabetes, hypertension, hyperlipidemia, endocarditis, coronary artery disease and heart failure with reduced ejection fraction. Patient underwent coronary artery bypass surgery and mitral valve replacement due to endocarditis nine years ago. Medications included aspirin, atorvastatin, carvedilol, clopidogrel, sacubitril-valsartan, warfarin and insulin. Immunosuppression regimen was tacrolimus (0.5 mg capsules: 2 capsules in the morning and 1 in the evening) and mycophenolic acid (720 mg 2 capsules a day). There were no known allergies to medications. He had smoked tobacco in the past but had quit 10 years earlier; he drank...
alcohol rarely and did not use illicit drugs for years. His family history included hypertension and heart disease in his father and throat cancer in his mother.

On examination, the temperature was 36.6°C, the blood pressure 90/58 mm Hg, the heart rate 103 beats per minute, and the oxygen saturation 98% while the patient was breathing ambient air. The body-mass index was 42.2. Heart sounds were normal and both lungs were clear on auscultation. The blood creatinine level of 6.7 mg/dL (reference range, 0.7–1.3 mg/dL) was higher than the level obtained 5 months earlier (2.5 mg/dL). The blood potassium level was 5.7 mMol/L (reference range, 3.5 to 5.1 mMol/L), the blood urea nitrogen 175 mg/dL (reference range 7–25 mg/dL) and the bicarbonate level 14 mMol/L (reference range, 21 to 31 mMol/L). The white-cell count was 2.9 K/CUMM (reference range, 3.5–10.6), with 0.2 K/CUMM lymphocytes count (reference range, 1.0–3.8). The international normalised ratio (INR) was 2.75 (reference range, 0.90–1.13). Other laboratory test results are summarized in Table 1. Radiography of the chest revealed prominent pulmonary vascular markings and enlarged cardiac silhouette. No evidence of pulmonary infiltrates, metabolic acidosis, leukopenia and mild thrombocytopenia (Table 1A). Nasopharyngeal swab tested positive for SARS-CoV-2 RNA.

Hypotension resolved after administration of 1 L of normal saline’s solution. Patient treated with insulin, beta-agonists, calcium and polyxylene sulfonates for hyperkalemia. The patient was admitted to the hospital.

On days 2 and 3 of hospitalization, vital signs remained largely stable. Patient had no respiratory symptoms and the oxygen saturation was 96% on room air. Patient’s symptoms of diarrhea, nausea and vomiting were resolved, and he was able to tolerate soft diet. Laboratory results on hospital day 3 reflected unresolved acute kidney injury, hyperkalemia, metabolic acidosis, leukopenia and mild thrombocytopenia (Table 1). Patient was oliguric since admission (Urine output <500 cc/24hrs). A transplant nephrology consultation was obtained. Levels of c-reactive protein, ferritin, lactate dehydrogenase and alkaline phosphatase (Table 1A) were normal and both lungs were clear on auscultation. The blood creatinine level of 6.7 mg/dL (reference range, 0.7–1.13) was higher than the level obtained 5 months earlier (2.5 mg/dL). The blood potassium level was 5.7 mMol/L (reference range, 3.5 to 5.1 mMol/L), the blood urea nitrogen 175 mg/dL (reference range 7–25 mg/dL) and the bicarbonate level 14 mMol/L (reference range, 21 to 31 mMol/L). The white-cell count was 2.9 K/CUMM (reference range, 3.5–10.6), with 0.2 K/CUMM lymphocytes count (reference range, 1.0–3.8). The international normalised ratio (INR) was 2.75 (reference range, 0.90–1.13).

On the morning of hospital day 4, patient reported productive cough and shortness of breath. Oxygen saturation decreased to 85% while the patient was breathing ambient air and then increased to 95% with the administration of oxygen through a nasal cannula at a rate of 3 L per minute. On the same morning, a dose of filgrastim, a granulocyte colony-stimulating factor (GCS-F), (480 mcg) was given to decrease the duration of leukopenia. Six hours later, shortness of breath progressed, and the oxygen saturation decreased. Patient was initiated on high-flow nasal cannula (HFNC) at a rate of 40 L per minute and transferred to the intensive care unit (ICU). Blood and sputum specimen obtained for culture. A chest radiograph obtained and showed development of multifocal air-space opacities, prominent pulmonary vascular markings and enlarged cardiac silhouette (Fig. 1B). Treatment with intravenous furosemide, vancomycin and cefepime were started for concern of volume overload and hospital-acquired pneumonia, respectively.

On day 5 of hospitalization, the patient underwent intubation and mechanical ventilation for worsening tachypnea and oxygen saturation. Blood pressure decreased to 75/44 mm Hg, and treatment with intravenous norepinephrine and vasopressin was initiated. Patient continued to have worsening kidney function (Table 1) and became anuric, so continuous renal replacement therapy (CRRT) was initiated. Impressively, white blood cell count increased after filgrastim administered from 2.5 K/CUMM (reference range, 3.5–10.6) on day 4 of hospitalization to 35 K/CUMM (reference range, 3.5–10.6) on day 5 of hospitalization. Levels of c-reactive protein, ferritin, lactate dehydrogenase and creatine phosphokinase were increased compared to levels measured on admission. Repeated chest radiograph showed worsening of bilateral opacities, prominent pulmonary vascular markings and enlarged cardiac silhouette. The endotracheal tube and the nasogastric tube were in the

| Variable                      | On admission | Hospital day 3 | Hospital day 4 | Hospital day 5 | Reference ranges |
|-------------------------------|--------------|----------------|----------------|----------------|------------------|
| Hematocrit, %                 | 31.6         | 26.5           | 25.7           | 27.5           | 38.9–49.7        |
| Hemoglobin, mg/dL             | 9.6          | 8.3            | 8.2            | 8.7            | 13.3–17.1        |
| White blood cell count, K/CUMM| 2.9          | 0.9            | 2.5            | 35             | 3.5–10.6         |
| Neutrophils                   | 2.4          | NA             | 2.2            | 28.9           | 1.58–7.13        |
| Lymphocytes                   | 0.2          | NA             | 0.2            | 0.3            | 1.0–3.8          |
| Monocytes                     | 0.2          | NA             | 0.1            | 0.9            | 0.1–0.88         |
| Eosinophils                   | 0.1          | NA             | 0.0            | 0.0            | 0.0–0.6          |
| Basophils                     | 0.0          | NA             | 0.0            | 0.0            | 0.0–0.2          |
| Platelet count, K/CUMM        | 146          | 124            | 114            | 140            | 150–450          |
| Prothrombin time, second(s)   | 26.8         | 42.2           | 44.0           | 83.1           | 9.4–11.7         |
| Partial thromboplastin time, second(s) | 41.2 | NA         | 50.1           | NA             | 23.1–33.1        |
| International normalised ratio (INR) | 2.75 | 4.48         | 4.68           | 9.24           | 0.90–1.13        |
| D-Dimer                      | 0.42         | NA             | 1.13           | 1.13           | 0.0–0.50         |
| Sodium, mMol/L               | 132          | 129            | 128            | 132            | 136–145          |
| Potassium, mMol/L            | 5.7          | 5.3            | 5.5            | 5.8            | 3.5–5.1          |
| Chloride, mMol/L             | 105          | 100            | 101            | 100            | 98–107           |
| Bicarbonate, mMol/L          | 14           | 15             | 13             | 15             | 21–31            |
| Anion gap, mMol/L            | 13           | 14             | 14             | 17             | 5–15             |
| Glucose, mg/dL               | 160          | 319            | 241            | 156            | 75–105           |
| Blood urea Nitrogen, mg/dL   | 175          | 156            | 164            | 113            | 7–25             |
| Creatinine, mg/dL            | 6.71         | 6.35           | 7.68           | 7.4            | 0.70–1.30        |
| Calcium, mg/dL               | 9.7          | 8.6            | 8.8            | 9.1            | 8.6–10.8         |
| Magnesium, mg/dL             | 2.0          | 1.6            | 2.4            | NA             | 1.6–3.0          |
| Alanine aminotransferase, U/L | 6            | 5              | NA             | NA             | 7–52             |
| Aspartate aminotransferase, U/L| 16         | 15             | NA             | NA             | 13–39            |
| Alkaline phosphatase, U/L    | 64           | 54             | NA             | NA             | 45–115           |
| Lactate dehydrogenase, U/L   | 330          | NA             | 774            | NA             | 140–271          |
| Creatine phosphokinase, U/L  | 154          | NA             | 601            | 390–223        | 13–52            |
| C-reactive protein, mg/L     | 6.8          | NA             | 101.4          | 0.0–5.0        |                  |
| Ferritin, ng/mL              | 1295         | NA             | 4681           | 24–336         |                  |
appropriate positions (Fig. 1C). Transthoracic echocardiography revealed an estimated left ventricular ejection fraction of 20% (similar to the ejection fraction measured 5 months before). The prosthetic mitral valve appears in normal position.

During the next four days, patient remained intubated on mechanical ventilation. Blood and sputum culture were negative. The oxygen saturation decreased required increasing the ventilator settings. Patient developed atrial fibrillation and intravenous amiodarone started. Hypotension progressively worsen required higher dose of vasopressors. CRRT was held due to worsening hypotension and tachycardia. Patient died on hospital day 9.

3. Discussion

We present a case with COVID-19 and neutropenia who deteriorated within 24 hours after G-CSF administration. To our knowledge, this is the second paper reporting the effect of G-CSFs in patient with COVID-19. The first paper [5] reported similar rapid deterioration in three patients with COVID-19 and neutropenia after G-CSF administration. Although G-CSFs therapy is known to be safe and well tolerated in most clinical settings [6,7], we will discuss here why G-CSFs therapy might be ineffective or even harmful in patients with COVID-19.

Treating neutropenia with G-CSFs in different clinical settings have failed to show any benefits [7]. G-CSFs therapy is recommended to be used only for prevention of neutropenia associated with chemotherapy or radiation as it has been shown to decrease duration of hospitalization and documented infections [8,9]. However, therapeutic use of G-CSFs in neutropenia due to acquired causes such as drugs or infections is not based on solid evidence and not routinely recommended [7–9].

G-CSF is known to drive excessive inflammatory reaction [2] and it might not be safe in patients with high inflammatory status. For example, a preexisting high serum levels of G-CSFs and interleukins play an important role in developing sweat syndrome, a side effect of G-CSFs characterized by neutrophilic infiltration of body organs [10]. One of the remarkable features of COVID-19 is the elevated proinflammatory cytokines including G-CSFs [3,4]. Therefore, G-CSFs therapy might worsen the overwhelming inflammatory reaction in COVID-19 and lead to worse outcomes. Also, targeting G-CSF might be a therapeutic option. A clinical trial (ClinicalTrials.gov Identifier: NCT04351152) is ongoing currently to assess the effect of lenzilumab, a monoclonal antibody against G-CSF, on patients with COVID-19.

G-CSF has been tried in patients with sepsis regardless of neutropenia, but no efficacy was shown [11]. Although G-CSF is found to be well tolerated in sepsis [11], not all patients with sepsis have high G-CSF level. Suratt BT [12] examined the serum level of G-CSF in patients with sepsis and found a bimodal or U-Shaped distribution. This might indicate that G-CSFs therapy should be carefully targeted as it might benefit patients with low G-CSF level and might harm patients with high G-CSF level.

Over the past few decades, there was a concern about G-CSFs-related pulmonary toxicity [13,14]. Neutrophils play a major role in the diffuse alveolar damage associated with acute respiratory distress syndrome (ARDS) [15]. It has been found that acute respiratory failure is directly related to neutropenia recovery after G-CSFs administration rather than G-CSF therapy itself [13,14]. Previous studies [13,14] showed that the median time to recovery of an absolute neutrophil count higher than 0.5 K/CUMM was two days after G-CSF administration. We observed in our COVID-19 case that neutrophil count recovered rapidly after G-CSF and this recovery is faster than previously known. Neutrophil count in our patient recovered from 2.5 K/CUMM to 35 K/CUMM (reference range, 3.5–10.6) 24 hours after 480 mcg dose of filgrastim. The previous paper [5] also reported rapid neutropenia recovery after 480 mcg dose of filgrastim in all three COVID-19 cases (case 1: 0.3 K/CUMM to 2.2 K/CUMM in 24 hours, case 2: 0.6 K/CUMM to 10.7 K/CUMM in 48hrs, case 3: 0.6K/CUMM to 7.5 K/CUMM in 24hrs). This fast neutropenia recovery observed in our case and the previous cases might explain the rapid respiratory deterioration.

It is important to keep in mind that the respiratory deterioration after
G-CSF administration described in our cases can be a coincidence. The respiratory deterioration cannot be attributable to G-CSFs without large randomized studies. Additionally, not all COVID-19 patients might have rapid neutropenia recovery after G-CSF therapy as observed in our cases. In summary, the safety and efficacy of G-CSFs in COVID-19 patients should be carefully reassessed. Clinicians should be aware of increased risk of acute respiratory failure during G-CSF induced neutropenia recovery in patients with COVID-19.

Reprints

No reprints will be ordered.

Source of funding and methods

No funding received from any organizations.

Consent for case report had been obtained from the patient family.

Declaration of competing Interest

None of the authors have any conflicts of interests to report.

References

[1] D. Wang, Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in wuhan, China, J. Am. Med. Assoc. ; J. Am. Med. Assoc. 323 (11) (02/2020) 1061, https://doi.org/10.1001/jama.2020.1585.
[2] J.A. Hamilton, GM-CSF in inflammation, J. Exp. Med. 217 (2020), e20190945.
[3] W. Wang, J. He, Lie puyi, et al. The definition and risks of Cytokine Release Syndrome-Like in 11 COVID-19-Infected Pneumonia critically ill patients: disease Characteristics and Retrospective Analysis, Intensive Care and Critical Care Medicine (2020), https://doi.org/10.1101/2020.02.26.20026989.
[4] Z. Yonggang, F. Binqing, Z. Xiaohu, et al., Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus, bioRxiv 2 (12) (2020) 945576.
[5] T. Nawar, S. Morjaria, A. Kaltas, et al., Granulocyte-colony stimulating factor in COVID-19: is it stimulating more than just the bone marrow? [published online ahead of print, 2020 May 17], Am. J. Hematol. (2020), https://doi.org/10.1002/ ajh.25970.
[6] P. Anderlini, Biologic and molecular effects of granulocyte colony-stimulating factor in healthy individuals: recent findings and current challenges, Blood 111 (4) (02/2008) 1767–1772, https://doi.org/10.1182/blood-2007-07-097543.
[7] https://www.uptodate.com/contents/introduction-to-recombinant-hematopoietic-growth-factors?search=granulocyte%20colony%20stimulating%20factor&sectionRank=1&usage_type=default&anchor=H5&source=machineLearning&selectedTitle=2~150&display_rank=2#H4.
[8] T.J. Smith, Recommendations for the use of WBC growth factors: American society of clinical oncology clinical practice guideline update, J. Clin. Oncol. 33 (28) (10/2015) 3199–3212, https://doi.org/10.1200/JCO.2015.62.3488.
[9] A.G. Freifeld, Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America, Clin. Infect. Dis. 52 (4) (02/2011) e56–e93, https://doi.org/10.1093/cid/cir073.
[10] S. Bidyasar, Sweet syndrome associated with granulocyte colony-stimulating factor, J. Clin. Oncol. 26 (26) (09/2008) 4355–4356, https://doi.org/10.1200/JCO.2008.16.2933.
[11] B. Mathias, B.E. Sepila, F.A. Moore, et al., A review of GM-CSF therapy in sepsis, Medicine (Baltim.) 94 (50) (2015), e2044, https://doi.org/10.1097/MD.0000000000002044.
[12] B.T. Saratt, M.D. Eisner, C.S. Calfee, et al., Plasma granulocyte colony-stimulating factor levels correlate with clinical outcomes in patients with acute lung injury, Crit. Care Med. 37 (4) (2009) 1322-1328, https://doi.org/10.1097/CCM.0b013e31819c14fa.
[13] M. Balasat, A. Xhaard, E. Lengline, et al., Worsening of respiratory status during neutropenia recovery in noncritically ill hematological patients: results of a prospective multicenter study, Respiration 90 (2015) 229–234, https://doi.org/10.1159/000433556.
[14] M. Xavier, B. Lucie, L. Virginie, et al., Granulocyte colony-stimulating factor and respiratory status of critically ill neutropenic patients with hematologic malignancies, Leuk. Lymphoma 60 (5) (2019) 1156–1163, https://doi.org/10.1080/10428194.2018.1516874.
[15] R.L. Zemans, M.A. Matthay, What drives neutrophils to the alveoli in ARDS? Thorax 72 (1) (2017) 1-3, https://doi.org/10.1136/thoraxjnl-2016-209170.